Introduction
The non-obese diabetic (NOD) mouse is a spontaneous animal model of the human autoimmune disease, insulin-dependent diabetes mellitus (IDDM) [ 11. In this mouse model, mononuclear cell infiltration in the pancreas is evident in both sexes from 5 to 6 weeks of age. Disease development resulting from a progressive intra-islet infiltration and B-cell destruction occurs in many colonies, predominantly in female mice, from 30 weeks of age.
The development of IDDM in the NOD mouse is dependent on T cells and the disease can be passively transferred by a combination of CD4 + and CD8 + splenic T cells from a diabetic donor but not by either CD4+ or CD8+ T cells alone [2] . Macrophages are the only phagocytic cells detected in pancreatic lesions in the resulting diabetic animals. Macrophages seem to play a role in /%cell destruction as disease development can be inhibited by treatment of NOD mice with silica or antibodies directed towards the CR3 receptor on these cells [ 3 ] , and these treatments inhibit phagocytosis or binding, respectively. As in man, the disease in the NOD mouse has been shown to be under polygenic control with at least one gene linked to the class I1 region of the major histocompatibility complex (MHC). The NOD mouse has unusual features in the MHC class I1 region. This animal does not express I-E antigens because of a deletion in the promoter region of I-Ea and the sequence of its I-Ap is unique [4, 
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Analysis of DQ /3-chain (human homologue of murine I-AB) sequences in man suggested that the presence of an aspartic acid at position 57 conferred resistance to the development of IDDM [6] . As the I-@ chain of most mouse strains encodes an aspartate at position 57, whereas the NOD I-AB has a serine at this position, it was suggested that this amino acid residue might also be of importance in Abbreviations used: NOL), non-obese diabetic; IL)I)M, insulin-dependent diabetes mellitus; MHC, major histocompatibility complex; PHS, phosphate-buffered saline. *To whom correspondence should be addressed.
determining susceptibility or resistance to IDDM in mice.
We have performed a series of experiments designed to address the role of different subpopulations of lymphocytes in the development of IDDM in the mouse model as well as the role of different MHC genes in conferring susceptibility to the development of IDDM [7] . In this paper, we describe some of the experiments which demonstrate the obligatory role of at least three separate subpopulations of mononuclear cells in the chain of events leading to IDDM.
Materials and methods

Mice
A breeding nucleus was established at the C.RC., Northwick Park (NODXRC) from mice provided by Dr E. Leiter, Jackson Laboratory, Bar Harbour, USA.
Antibodies
Rat monoclonal antibodies to mouse cell surface antigens were prepared as ascites fluid in LOU x DA rats pretreated with pristane. Antibodies were prepared by ammonium sulphate (14%, w/v) precipitation and the Ig content was determined by SDWPAGE. For injection into mice the antibodies were diluted in 10 mwsodium phosphate, 145 mMNaCI, pH 7.0 phosphate-buffered saline (PBS). The antigenic specificities, Ig subclass and code of the antibodies used are as follows: [8] 
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Transfer of diabetes
Whole spleen cells from overtly diabetic NOD mice, usually female, were prepared as single cell suspensions in Hanks' balanced salt solution and 2 X lo7 cells were injected intravenously into disease-free 2-3-month-old male recipients which were given 650 rads (a sub-lethal dose) earlier the same day (cobalt source). After transfer, the recipients were monitored at least weekly for the development of diabetes, the clinical onset of which was judged by the presence of glucose in the blood and urine. Urine was tested using 'Diastix' reagent strips (Miles Laboratories) and blood samples were tested using a Beckman glucose analyser or a Glucometer (Ames Division, Miles Laboratories). A consistent blood glucose reading of < 10 mM/iitre coupled with a positive test by 'Diastix' was considered to be an indication of overt diabetes. When T cell lines were used to induce disease, lo7 washed cells were injected intravenously with or without lo7 diabetic donor spleen cells depleted of either CD4 + or CD8 + T cells as described above.
T cell depletions in vivo
Rat monoclonal antibodies to mouse T cell surface antigens were used to treat (a) irradiated recipients of spleen cells, or (b) diabetic donor mice. intravenously on day one and the same amount intraperitoneally on the following two days. Control mice were treated with either YTH 3.2.6 or with PBS alone. Treatment of recipients with the antibody YTS 177.9.6.1, which does not lead to depletion of CD4 -i-T cells, but binds specifically to this cell population, was as follows: NOD mice recipients were injected with YTS 177.9.6.1 (2 mg) on three consecutive days prior to transfer of spleen cells from donor diabetic NOD mice. Recipient mice were then injected with YTS 177.9.6.1 three times per week throughout the course of the experiment. The initial injection was intraventricular and all subsequent injections were intraperitoneal.
(b) Diabetic donor mice were treated with YTS 169.4 or YTS 191.1 to enrich spleen cells for either CD4+ or CD8+ T cells, respectively. Donor mice were injected with these antibodies on three consecutive days prior to sacrifice. The injection schedule was as described above for recipient mice. 
The role of T cells in the development of IDDM
When spleen cells from a diabetic donor are transferred into an irradiated recipient of the same NOD strain, IDDM is passively transferred. Monoclonal antibodies specific for CD4 + or CD8 + T cells can be employed to treat recipients of such diabetic spleen cells to assess the relative roles of these two T cell subpopulations in disease development.
(a) Treatment with anti-CD4 antibodies prevents transfer of IDDM It can be seen from Table 1 that treatment of recipients with anti-CD4 antibodies (the non-depleting antibody YTS 177.9.6.1) completely prevents the sucessful transfer of IDDM by diabetic spleen cells.
(b) Treatment with anti-CD8 antibodies prevents transfer of IDDM
Administration of anti-CD8 antibodies (the depleting monoclonal, YTS 169.4) within two weeks after diabetic spleen cell transfer prevented the onset of IDDM in recipient mice (Fig. 1) . If anti-CD8 treatment was delayed until two weeks or later, the protective effect of this antibody was lost.
Detailed histological analysis of the pancreas of treated animals revealed that depletion of CD8 + cells within two weeks of transfer of spleen cells from a diabetic animal prevented intra-islet infiltration by CD4 + T cells and macrophages (Fig. 1) . It
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Autoimmunity should, however, be stated that peri-islet infiltration by all these cell types was still present. Peri-islet infiltration is frequently observed in young prediabetic mice of both sexes but does not necessarily progress to overt disease especially in males. A further signal, at present unknown and which appears to be overcome in anti-CD8 treated animals, facilitates invasion of islets and the final destruction of the B-cell. The results of this experiment are presented in Table 2 . It can be seen from this Table that (Table 26 ) and addition of the CD4 + T cell line also restored the ability of such CD8+ T cells to mediate an intra-islet infiltration (Table 2a) .
Our previous studies have shown that intraislet infiltration by T cells and macrophages induces an increase in class I MHC antigen expression in all endocrine cells in the islet and in exocrine cells adjacent to the area of infiltration. Islets in the pancreas of animals receiving a combination of CD8 + T cells with either CD4+ T cells from a diabetic spleen or CD4+ cells from a T cell line, manifest increased class I MHC antigen expression whereas islets in the pancreas of animals receiving only CD8+ T cell enriched splenocytes did not show increased MHC class I expression (Table 2a) .
In addition to T cells, the intra-islet infiltration observed in the prediabetic pancreas is also composed of mature inflammatory macrophages. 
Discussion
The development of IDDM in the NOD mouse has been shown to require CD4+ T cells, CD8+ T cells and additionally, macrophages. Intra-islet infiltration by such cells results in pancreatic @-cell destruction but the exact mechanism by which such specific destruction is effected remains to be clarified.
The hyperexpression of class I MHC antigens on the pre-diabetic pancreatic endocrine and exocrine makes it tempting to assume that the @-cell is selectively destroyed by a CD8 + (class I restricted) T cell. However, studies demonstrating the exquisite sensitivity of @-cells to macrophage-derived products [14] , as well as the presence of inflamma- Table 2 CD8 + T cells require CD4 + T cells to mediate intra-islet infiltration and diabetes N.D., not determined. *Spleen cells enriched for CD4 + and CD8 + T cells were taken from diabetic donors depleted in vivo with monoclonal antibodies as described in the Methods section. lo7 cells of each subpopulation and/or T line cells, were injected intravenously into irradiated recipients which were sacrificed at 2 weeks for immunohistological studies or monitored for diabetes until week 4. 
